AEZS - Aeterna Zentaris Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.5100
-0.1500 (-4.10%)
At close: 4:00PM EST

3.48 -0.03 (-0.85%)
After hours: 4:07PM EST

Stock chart is not supported by your current browser
Previous Close3.6600
Open3.7000
Bid3.48 x 800
Ask3.58 x 1000
Day's Range3.4500 - 3.7250
52 Week Range1.1200 - 3.9200
Volume458,181
Avg. Volume619,961
Market Cap57.601M
Beta (3Y Monthly)1.55
PE Ratio (TTM)6.57
EPS (TTM)0.53
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • Aeterna Zentaris (AEZS) Stock Moves -0.54%: What You Should Know
    Zacks3 days ago

    Aeterna Zentaris (AEZS) Stock Moves -0.54%: What You Should Know

    Aeterna Zentaris (AEZS) closed at $3.67 in the latest trading session, marking a -0.54% move from the prior day.

  • Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?
    Zacks6 days ago

    Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?

    Is (AEZS) Outperforming Other Medical Stocks This Year?

  • Can The Uptrend Continue for Aeterna Zentaris (AEZS)?
    Zacks10 days ago

    Can The Uptrend Continue for Aeterna Zentaris (AEZS)?

    Investors certainly have to be happy with Aeterna Zentaris Inc. (AEZS) and its short term performance.

  • ACCESSWIRE21 days ago

    4 Healthcare Stocks Taking a New Approach to Growth Trends

    CORAL GABLES, FL / ACCESSWIRE / November 19, 2018 / Healthcare stocks have rallied during the last 3 trading sessions. On Friday, the market powered higher, lead by healthcare stocks. Furthermore, the idea that a split congress could be a good thing for healthcare stocks is offering a brighter outlook for some investors to look closer at several smaller healthcare companies that could be set to rebound.

  • GlobeNewswire21 days ago

    Aeterna Zentaris (AEZS) Receives Positive CHMP Opinion of Macimorelin for Diagnosis of Adult Growth Hormone Deficiency

    Aeterna Zentaris Inc. (AEZS) (AEZS), announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a marketing authorization for macimorelin, an orally available ghrelin agonist, for diagnosis of adult growth hormone deficiency (AGHD). The recommendation will now be reviewed by the European Commission. “We are pleased with the CHMP’s positive opinion of macimorelin for AGHD,” said Michael V. Ward, Chief Executive Officer of Aeterna Zentaris.

  • ACCESSWIRE24 days ago

    4 Healthcare Stocks Turning Toward Tech For New Growth

    CORAL GABLES, FL / ACCESSWIRE / November 16,2018 / There's no denying the progress that the healthcare industry has made. According to analyst firm Market Research Engine, the E-Health Market is expected to exceed more than US$136 Billion by 2024 at a CAGR of 21% in the given forecast period. Bank of America surveyed** 225 fund managers with $641 billion in assets under management, who said the most "crowded trade" is in tech stocks.

  • GlobeNewswire24 days ago

    Consolidated Research: 2018 Summary Expectations for Western Gas Partners, LP, HCA Healthcare, DHI Group, AEterna Zentaris, Tsakos Energy Navigation, and Acme United — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Associated Presslast month

    Aeterna Zentaris: 3Q Earnings Snapshot

    The Summerville, South Carolina-based company said it had a loss of 15 cents per share. The drug developer posted revenue of $663,000 in the period. In the final minutes of trading on Tuesday, the company's ...

  • GlobeNewswirelast month

    Aeterna Zentaris Reports Third Quarter 2018 Financial and Operating Results

    CHARLESTON, S.C., Nov. 06, 2018 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), a biopharmaceutical company engaged in developing and commercializing pharmaceutical.

  • GlobeNewswirelast month

    Aeterna Zentaris Settles Dispute with Cogas Consulting, LLC

    CHARLESTON, S.C., Nov. 06, 2018 -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS) and Cogas Consulting, LLC have amicably resolved their dispute with Aeterna Zentaris Inc..

  • ACCESSWIRElast month

    Aeterna Zentaris Soars on Macrilen(TM) Out Licensing Deal, Analysts Review and Target

    NEW YORK, NY / ACCESSWIRE / November 1, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Aeterna Zentaris Inc. (AEZS), a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. In intra-day trading on October 31, 2018, Aeterna Zentaris is at $2.11 per share (+62.31%) in reaction to Strongbridge Biopharma's out-licensing deal with Novo Nordisk for U.S. and Canadian rights to the AEZS drug MACRILEN (macimorelin). Details of the Macrilen™ and the Novo Nordisk deal and analysts review here READ MORE.

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: Aeterna Zentaris and AbbVie

    NEW YORK, NY / ACCESSWIRE / November 1, 2018 / Aeterna Zentaris saw its shares climbing as Wall Street learned about Novo Nordisk and Strongbridge Biopharma’s deal where Aeterna Zentaris stands to capitalize. ...

  • ACCESSWIRElast month

    3 Healthcare Stocks Leading New Industry Trends

    CORAL GABLES, FL / ACCESSWIRE / October 31,2018 / Institutional investors' focus onhealthcare services has grown over the last several quarters. "Institutional investors have been learning from their experience and will likely be using those lessons as they inject hundreds of billions in capital into healthcare in the next five years. As these trends continue to foster investment, companies like Premier Health Group, Inc. (PHGRF) (PHGI.CN), Aeterna Zentaris Inc. (AEZS)(TSX:AEZS.TO) and Veracyte, Inc. (VCYT) could be positioned to capitalize on this growth.

  • GlobeNewswire2 months ago

    Aeterna Zentaris Appoints Leslie Auld as Chief Financial Officer

    Aeterna Zentaris Inc. (AEZS) (AEZS.TO), a biopharmaceutical company engaged in developing and commercializing pharmaceutical products, today announced the appointment of Leslie Auld as Senior Vice President, Chief Financial Officer. Ms. Auld has over twenty-five years of accounting, finance and pharmaceutical industry experience, with increasingly senior roles at PricewaterhouseCoopers, Helix BioPharma Corp., Luminex Diagnostics (formerly TM BioScience Corp.), Attwell Capital Inc. (formerly Fralex Therapeutics) and GeneNews Limited.

  • What is Behind Aeterna Zentaris Inc’s (TSE:AEZS) Superior ROE?
    Simply Wall St.4 months ago

    What is Behind Aeterna Zentaris Inc’s (TSE:AEZS) Superior ROE?

    This article is intended for those of you who are at the beginning of your investing journey and want to learn about Return on Equity using a real-life example. WithRead More...

  • ACCESSWIRE4 months ago

    Aeterna Zentaris Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 10, 2018 / Aeterna Zentaris Inc. (NASDAQ: AEZS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 10, 2018 at 8:30 AM Eastern ...

  • Associated Press4 months ago

    Aeterna Zentaris: 2Q Earnings Snapshot

    The Summerville, South Carolina-based company said it had a loss of 16 cents per share. The drug developer posted revenue of $168,000 in the period. In the final minutes of trading on Thursday, the company's ...

  • Mirati Therapeutics (MRTX) Soars: Stock Adds 13.6% in Session
    Zacks6 months ago

    Mirati Therapeutics (MRTX) Soars: Stock Adds 13.6% in Session

    Mirati Therapeutics (MRTX) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes.

  • VIVUS (VVUS) in Focus: Stock Moves 5.6% Higher
    Zacks7 months ago

    VIVUS (VVUS) in Focus: Stock Moves 5.6% Higher

    VIVUS (VVUS) was a big mover last session, as the company saw its shares rise nearly 6% on the day.

  • MiMedx Group (MDXG) Soars: Stock Adds 11.2% in Session
    Zacks7 months ago

    MiMedx Group (MDXG) Soars: Stock Adds 11.2% in Session

    MiMedx Group (MDXG) shares rose more than 11% in the last trading session, amid huge volumes.